161 related articles for article (PubMed ID: 11385958)
41. Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model.
Marshall D; Pedley RB; Boden JA; Boden R; Begent RH
Br J Cancer; 1994 Mar; 69(3):502-7. PubMed ID: 8123481
[TBL] [Abstract][Full Text] [Related]
42. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody.
Ueno A; Arakawa F; Abe H; Matsumoto H; Kudo T; Asano R; Tsumoto K; Kumagai I; Kuroki M; Kuroki M
Anticancer Res; 2002; 22(2A):769-76. PubMed ID: 12014649
[TBL] [Abstract][Full Text] [Related]
43. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts.
Hu S; Shively L; Raubitschek A; Sherman M; Williams LE; Wong JY; Shively JE; Wu AM
Cancer Res; 1996 Jul; 56(13):3055-61. PubMed ID: 8674062
[TBL] [Abstract][Full Text] [Related]
44. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
[TBL] [Abstract][Full Text] [Related]
45. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.
Knox SJ; Goris ML; Tempero M; Weiden PL; Gentner L; Breitz H; Adams GP; Axworthy D; Gaffigan S; Bryan K; Fisher DR; Colcher D; Horak ID; Weiner LM
Clin Cancer Res; 2000 Feb; 6(2):406-14. PubMed ID: 10690517
[TBL] [Abstract][Full Text] [Related]
46. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
[TBL] [Abstract][Full Text] [Related]
47. Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein.
Bhatia J; Sharma SK; Chester KA; Pedley RB; Boden RW; Read DA; Boxer GM; Michael NP; Begent RH
Int J Cancer; 2000 Feb; 85(4):571-7. PubMed ID: 10699932
[TBL] [Abstract][Full Text] [Related]
48. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF
J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
[TBL] [Abstract][Full Text] [Related]
49. Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.
Wilbur DS; Park SI; Chyan MK; Wan F; Hamlin DK; Shenoi J; Lin Y; Wilbur SM; Buchegger F; Pantelias A; Pagel JM; Press OW
Bioconjug Chem; 2010 Jul; 21(7):1225-38. PubMed ID: 20597486
[TBL] [Abstract][Full Text] [Related]
50. Recombinant single-chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor.
Liu Y; Cheung LH; Marks JW; Rosenblum MG
Int J Cancer; 2004 Feb; 108(4):549-57. PubMed ID: 14696119
[TBL] [Abstract][Full Text] [Related]
51. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
[TBL] [Abstract][Full Text] [Related]
52. Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.
Forero-Torres A; Shen S; Breitz H; Sims RB; Axworthy DB; Khazaeli MB; Chen KH; Percent I; Besh S; LoBuglio AF; Meredith RF
Cancer Biother Radiopharm; 2005 Aug; 20(4):379-90. PubMed ID: 16114986
[TBL] [Abstract][Full Text] [Related]
53. Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapy.
Leigh BR; Burke PA; Hong AM; O'Donnell RT; Howell LP; Miers LA; DeNardo GL; DeNardo SJ
Cancer Biother Radiopharm; 1999 Apr; 14(2):113-9. PubMed ID: 10850294
[TBL] [Abstract][Full Text] [Related]
54. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
Buchsbaum D; Khazaeli MB; Liu T; Bright S; Richardson K; Jones M; Meredith R
Cancer Res; 1995 Dec; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
[TBL] [Abstract][Full Text] [Related]
55. Increased streptavidin uptake in tumors pretargeted with biotinylated antibody using a conjugate of streptavidin-fab fragment.
Yao Z; Zhang M; Sakahara H; Saga T; Kobayashi H; Nakamoto Y; Toyama S; Konishi J
Nucl Med Biol; 1998 Aug; 25(6):557-60. PubMed ID: 9751423
[TBL] [Abstract][Full Text] [Related]
56. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex.
Cheal SM; Xu H; Guo HF; Zanzonico PB; Larson SM; Cheung NK
Mol Cancer Ther; 2014 Jul; 13(7):1803-12. PubMed ID: 24944121
[TBL] [Abstract][Full Text] [Related]
57. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
[TBL] [Abstract][Full Text] [Related]
58. Biodistribution and radioimmunotherapy of SCCHN in xenotransplantated SCID mice with a 131I-labelled anti-EpCAM monoclonal antibody.
Andratschke M; Gildehaus FJ; Johannson V; Schmitt B; Mack B; Reisbach G; Lang S; Lindhofer H; Zeidler R; Wollenberg B; Luebbers CW
Anticancer Res; 2007; 27(1A):431-6. PubMed ID: 17352264
[TBL] [Abstract][Full Text] [Related]
59. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
Gold DV; Goldenberg DM; Karacay H; Rossi EA; Chang CH; Cardillo TM; McBride WJ; Sharkey RM
Cancer Res; 2008 Jun; 68(12):4819-26. PubMed ID: 18559529
[TBL] [Abstract][Full Text] [Related]
60. In vivo biotinylated recombinant antibodies: construction, characterization, and application of a bifunctional Fab-BCCP fusion protein produced in Escherichia coli.
Weiss E; Chatellier J; Orfanoudakis G
Protein Expr Purif; 1994 Oct; 5(5):509-17. PubMed ID: 7827508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
